It has recently been shown (Desgranges et al., 1986) that bromovinyluracil [BVU: (E)-5-(2-bromovinyl)uracil] increases the antitumour effect of 5-fluorouracil (5-FU) in DBA/2 mice inoculated with P388 leukaemia cells, most likely by inhibiting 5-FU degradation in vivo. The inhibitory effect is apparently due to the effect of BVU on dihydrothymine dehydrogenase, the rate-limiting enzyme in the catabolism of pyrimidines. It has also been reported that bromovinyldeoxyuridine [BVDU; (E)-5-(2-bromovinyl)-2'-deoxyuridine] is rapidly converted to BVU in vivo (Desgranges et al., 1984) and induces the same synergistic antitumour effect with 5-FU as observed upon injection of BVU (Desgranges et al., 1986) . BVDU itself is an antiviral compound with great promise for the treatment of herpes simplex virus (type 1) and varicella-zoster virus infections (de Clercq & Walker, 1984) .
It has recently been shown (Desgranges et al., 1986) that bromovinyluracil [BVU: (E)-5-(2-bromovinyl)uracil] increases the antitumour effect of 5-fluorouracil (5-FU) in DBA/2 mice inoculated with P388 leukaemia cells, most likely by inhibiting 5-FU degradation in vivo. The inhibitory effect is apparently due to the effect of BVU on dihydrothymine dehydrogenase, the rate-limiting enzyme in the catabolism of pyrimidines. It has also been reported that bromovinyldeoxyuridine [BVDU; (E)-5-(2-bromovinyl)-2'-deoxyuridine] is rapidly converted to BVU in vivo (Desgranges et al., 1984) and induces the same synergistic antitumour effect with 5-FU as observed upon injection of BVU (Desgranges et al., 1986) . BVDU itself is an antiviral compound with great promise for the treatment of herpes simplex virus (type 1) and varicella-zoster virus infections (de Clercq & Walker, 1984) .
We have shown (Ben-Efraim et al., 1986 ) that treatment of MOPC-315 plasmacytoma tumour cells for 1 h with a minimal dose of 0. Ipg 5-FU/107 cells caused marked reduction in incorporation of (methyl)3H thymidine (up to 68% of the degree of thymidine incorporation in control untreated cells). No attempts were made to determine the effect of extending the length of the 5-FU treatment interval on tumour cells. In view of results obtained with other tumour lines (Drewinko & Yang, 1985) , it might be that extending the length of 5-FU treatment of tumour cells will result in more marked inhibition of thymidine incorporation and possibly in reduction of the minimal effective dose of The data indicating tumouricidal effect The MOPC-315 myeloma cell line employed in this study grows preferentially in the mouse BALB/c strain and is characterized by its ability to secrete anti-TNP trinitrophenyl) IgAA2 immunoglobulin (Eisen et al., 1968) . Subcutaneous inoculation of 1 x 105 MOPC-315 tumour cells invariably induces formation of local tumour which reach a size of 15.0 mm on the 11th day after inoculation and death within 20 days. An in vitro line of MOPC-315 tumour cells, adapted to growth in culture (Yaniv et al., 1978) , was maintained in RPMI 1640 medium (GIBCO, NY, USA), supplemented with 100 U ml-1 penicillin, 100 igml-1 streptomycin, 2 mmol ml-1 L-glutamine, and 10% foetal calf serum. The MOPC-315 cell line was used for evaluating the in vitro effects of BVDU and 5-FU on (methyl)3H thymidine (Nuclear Research Centre, Negev, Israel; 1.0 pCi/50 Ml/culture) incorporation in tumour cells. BVDU was synthesized at the Rega Institute for Medical Research Leuven, Belgium following a described procedure (Jones et al., 1979) . 5-FU was kindly donated by Abic, Ramat-Gan, Israel. The effect of BVDU and 5-FU on MOPC-315 tumour cells in vitro were monitored in incubating 1 x 107 cells with varying compound concentrations for 1 h at 37°C, washing the cells with serum-free medium and further incubating the cell cultures as described (Bocian et al., 1984 on the synergistic antitumour activity of BVDU and 5-FU in DBA/2 mice inoculated with P388 leukaemia cells. BVDU alone does not affect MOPC-315 tumour cells either in vitro or in vivo. Since BVDU is readily converted in vivo to BVU (Desgranges et al., 1984) and since BVU is capable of inhibiting the degradation of 5-FU in vivo (Desgranges et al., 1986) , one may postulate that the increased antitumour activity of combined BVDU and 5-FU therapy in the MOPC-315 model is due to a decrease in the degradation of 5-FU, and hence greater bio-availability of the compound.
Under the experimental conditions used (i.e. single doses of both BVDU and 5-FU), only a transient regression of MOPC-315 tumours was observed. It would seem imperative to examine whether a more intensive treatment regimen, i.e. higher doses of BVDU and/or repeated administrations of BVDU and 5-FU, may yield a more definitive prolonged or even definitive regression of MOPC-315 tumours. In any case, the combination of 5-FU and BVDU is an interesting lead that should be further pursued as a therapeutic modality in the treatment of cancer. Improvement in effectiveness of 5-FU therapy may be of importance in view of the doubts expressed (Drewinko & Yang, 1985) on the efficacy of therapy with this drug alone. 1 (----) inoculated, untreated mice. 2 (. ) inoculated, 5-FU 100 (mgkg-).
3 (---) inoculated, 5-FU 100 (mg kg-1) + BVDU 69.5 (mg kg1). 4 (------) inoculated, 5-FU 50 (mg kg-1). 5 (---) inoculated, 5-FU 50 (mg kg-1) + BVDU 69.5 (mg kg1). 6 (-) inoculated, BVDU 69.5 (mg kg-1).
(b) Survival times after inoculation with MOPC-315 tumour cells and treatment with bromovinyldeoxyuridine (BVDU) and 5-fluorouracil (5-FU).
1 (---) inoculated, untreated mice. 2 C. ) inoculated, 5-FU 25 (mg kg -). 3 (----) inoculated, 5-FU 25 (mg kg-1) + BVDU 69.5 (mg kg1). 4 (-) inoculated, 5-FU 12.5 (mgkg-'). 5 (---) inoculated, 5-FU 12.5 (mg kg-1) + BVDU 69.5 (mg kg1). 
